Drug Profile


Alternative Names: 226256-56-0; AMG-073; Cinacalcet HCL; Cinacalcet hydrochloride; KRN-1493; Mimpara; NPS-1493; Regpara; Sensipar

Latest Information Update: 10 Jul 2017

Price : $50

At a glance

  • Originator NPS Pharmaceuticals
  • Developer Amgen; Kirin Holdings Company
  • Class Naphthalenes
  • Mechanism of Action Calcium channel agonists; Parathyroid hormone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypercalcaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypercalcaemia; Primary hyperparathyroidism; Secondary hyperparathyroidism
  • No development reported Cardiovascular disorders

Most Recent Events

  • 23 Jun 2017 Preregistration for Secondary hyperparathyroidism (In adolescents, In children) in European Union (PO) before June 2017
  • 23 Jun 2017 The EMA's CHMP adopts a positive opinion for cinacalcet in Secondary hyperparathyroidism (In children, Treatment-experienced)
  • 15 Mar 2017 Amgen completes a phase III extension trial in Secondary hyperparathyroidism (In adolescents, In children) in USA, Belgium, Czech Republic, France, Germany, Greece, Hungary, Italy, Poland, Russia and Ukraine (NCT02341417)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top